` IMRX (Immuneering Corp) vs S&P 500 Comparison - Alpha Spread

I
IMRX
vs
S&P 500

Over the past 12 months, IMRX has significantly outperformed S&P 500, delivering a return of +256% compared to the S&P 500's +13% growth.

Stocks Performance
IMRX vs S&P 500

Loading
IMRX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
IMRX vs S&P 500

Loading
IMRX
S&P 500
Difference
www.alphaspread.com

Performance By Year
IMRX vs S&P 500

Loading
IMRX
S&P 500
Add Stock

Competitors Performance
Immuneering Corp vs Peers

S&P 500
IMRX
ABBV
AMGN
GILD
VRTX
Add Stock

Immuneering Corp
Glance View

Market Cap
152.6m USD
Industry
Biotechnology

Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.

IMRX Intrinsic Value
Not Available
I
Back to Top